

Summary:

The invention refers to the use of non-neurotoxic plasminogen activating factors, e.g. from *Desmodus rotundus* (DSPA) or of genetically modified plasminogen activating factors, in particular of human origin, for the production of a pharmaceutical for injection for the therapeutic treatment of stroke in humans.